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ABSTRACT  
ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and 
endometrioid carcinomas of the ovary and endometrium and is an important clinical 
biomarker for novel treatment approaches for patients with ARID1A defects. 
However, the accuracy of ARID1A immunohistochemistry (IHC) as a surrogate for 
mutation status has not fully been established for patient stratification in clinical trials. 
Here we tested whether ARID1A immunohistochemistry could reliably predict 
ARID1A mutations identified by next-generation sequencing. Three commercially 
available antibodies - EPR13501 (Abcam), D2A8U (Cell Signaling) and HPA005456 
(Sigma) – were optimised for IHC using cell line models and human tissue, and 
screened across a cohort of 45 rare gynaecological tumours. IHC was scored 
independently by three pathologists using an immunoreactive score. ARID1A 
mutation status was assessed using 2 independent sequencing platforms and the 
concordance between ARID1A mutation and protein expresssion was evaluated 
using Receiver Operator Characteristics statistics.  Overall, 21 ARID1A mutations in 
14/43 assessable tumours (33%) were identified, the majority of which were 
predicted to be deleterious. Mutations were identified in 7/18 (39%) ovarian clear cell 
carcinomas, (4/7 (57%) of ovarian endometrioid carcinomas, 2/5 (40%) of 
endometrial carcinomas and 1/6 (17%) of carcinosarcomas. ROC analysis identified 
greater than 95% concordance between mutation status and IHC using a modified 
immunoreactive score for all three antibodies allowing a definitive cut-point for 
ARID1A mutant status to be calculated. Comprehensive assessment of concordance 
of ARID1A IHC and mutation status identified EPR13501, as an optimal antibody, 
with a 100% concordance between ARID1A mutation status and protein expression, 
across different gynaecological histological subtypes. It delivered the best inter-
observer agreement between all pathologists, as well as a a clear cost-benefit 
advantage. This could allow patients to be accurately stratified based on their 
ARID1A IHC status into early phase clinical trials.  
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INTRODUCTION  
Recent studies have highlighted that somatic loss of function mutations in the tumour 
suppressor gene ARID1A underpin 57% of ovarian clear cell carcinomas (OCCC)[1, 
2], 40% of uterine endometrioid carcinomas[3] and between 20-36% of uterine 
carcinosarcomas[4-6], however are rare in high-grade serous ovarian cancer 
(HGSOC)[1, 2]. HGSOC are underpinned by TP53 mutations, where p53 IHC is 
routinely used in clinical practice to aid diagnosis[7]. However, OCCC rarely harbour 
TP53 mutations; these differences in driver mutational profiles highlight the distinct 
aetiology of the two diseases. Moreover, the presence of ARID1A missense 
mutations may not alter ARID1A protein expression unlike TP53 missense mutations.  
Loss or significant reduction of ARID1A protein expression is associated with 
heterozygous ARID1A mutations[1, 8, 9], suggesting a dominant-negative tumour 
suppressor role (for a comprehensive review on this see[10]). ARID1A forms a key 
DNA binding subunit in the ATP dependent SWI/SNF chromatin-remodelling complex 
that modulates the winding of DNA around histone cores allowing access to the DNA 
to enable transcription, DNA repair and replication[11, 12], leading to aberrant cell 
cycle and loss of proliferation control[13]. Two genetically engineered mouse models 
(GEMM) have been created with ARID1A alterations which led to tumour formation 
with loss of ARID1A protein expression observed by IHC. The first was an ovarian 
endometrioid tumour with co-existent PTEN loss[14] and a more recently a GEMM 
harbouring both ARID1A loss and a PIK3CA (H1047R) mutation promoted ovarian 
clear-cell tumorigenesis[15].  ARID1A mutations are also detected at high 
frequencies in other solid tumours including 23% of pancreatic ductal 
adenocarcinoma (PDAC), 23% of advanced urothelial carcinomas, 18% 
hepatocellular carcinomas and 6% of metastatic castrate resistant prostate 
cancers[16-20].  
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Novel ways of treating patients with ARID1A mutations have focused largely on using 
synthetic-lethal approaches. Bitler et al highlighted the potential of targeting the 
antagonistic activity between SWI/SNF and EZH2 methyltransferase, with the EZH2 
small molecule inhibitors GSK126, that triggered apoptosis in ARID1A mutated 
cells[21]. This was mediated via upregulation of PIK31P1, a direct target of EZH2, 
and selectivity was further enhanced upon inhibition of PI3K-AKT signalling[21]. 
Subsequent work by Bitler et al has shown that ARID1A-mutated ovarian cancers are 
selectively dependent on HDAC6 activity, due to HDAC6 upregulation in ARID1A 
mutant cells that mechanistically inactivates the apoptosis-promoting function of 
TP53 due to deacetylation of lysine 120[22]. The work showed that treating ARID1A-
mutated tumours with the small molecule HDAC6 inhibitor, ACY1215, showed a 
survival benefit in vivo. Additional approaches identified reliance on the ARID1A 
paralog, ARID1B in mutant cells[23]. Our group has found ARID1A defective OCCC 
tumours can be targeted with the multi-kinase inhibitor dasatinib, mediated through 
addiction to the dasatinib target YES1[9] and more recently a profound sensitivity to 
inhibition of the DNA repair kinase, ATR, leading to premature mitotic entry, genomic 
instability and apoptosis[24]. Shen et al have additionally shown that loss of ARID1A 
leads to an impaired G2-M DNA damage checkpoint activation and repair of DNA 
double strand breaks (DSB), causing sensitivity to DSB inducing treatments such as 
the PARP inhibitor talozaparib, both in vitro and in vivo[25]. Together, these 
observations open up the possibility of assessing these therapeutic approaches in 
clinical trials, in particular, for tumour types with high frequencies of ARID1A 
mutations, such as OCCC. 
 
Currently there are no clinical trials recruiting patients that prospectively assess 
ARID1A mutational status. However, there are three early phase trials investigating 
ARID1A mutational status and response to therapy; the first of which allocates 
treatment to patients whose biopsies are sequenced as part of on-going clinical 
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sequencing programmes outside of the remit of the clinical trial[26]. Patients with 
PIK3CA, AKT or ARID1A mutations will receive olaparib with the AKT inhibitor 
AZD5363[26]. A second is a randomised phase II study of nintedanib (an oral 
tyrosine kinase inhibitor targeting VEGF receptor 1-3, FGFR 1-3 and PDGFR α and 
β) compared to chemotherapy in patients with clear cell carcinoma of the ovary or 
endometrium, which will assess ARID1A mutational status retrospectively and 
correlate with outcome[27]. A third trial which is ongoing, but not currently recruiting, 
will assess dasatinib in patients with recurrent or persistent ovarian, fallopian tube, 
endometrial or peritoneal cancer and will retrospectively compare ARID1A mutational 
and IHC status[28]. These trials highlight that prospectively assessing ARID1A 
mutational status is potentially cost-prohibitive and the turn-around time can make it 
difficult for trial recruitment. Therefore, a surrogate biomarker of mutational status 
such as IHC is needed. 
 
Despite the clinical importance of ARID1A mutations, rapid sequencing is not widely 
available hence immunohistochemistry (IHC) would be the commonest method to 
infer mutational status, highlighted by the fact that a number of open clinical open 
clinical trials are performing retrospective ARID1A mutational assessment. Studies 
that have so far assessed the correlation between ARID1A mutational status and 
IHC have demonstrated a good concordance[1, 3, 29] however the accuracy of IHC 
as a predictor of ARID1A mutation in ovarian carcinoma has not been precisely 
defined as there is no uniform scoring system or specific antibody that is 
recommended for IHC clinical use.  In the largest concordance study to date, 
Wiegand et al assessed ARID1A in 182 gynaecological tumours, defining positive 
staining as definitive nuclear staining and negative as no immunoreactivity[1]. There 
was a statistically significant correlation between the loss of ARID1A protein 
expression and ARID1A mutational status in both OCCC and endometrioid 
carcinomas[1].  In total, 73% of OCCC (27/37 cases) with a known ARID1A mutation 
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showed loss of ARID1A expression, however 11% of OCCC (4/36 cases) with no 
ARID1A mutation also showed loss of ARID1A protein expression[1]. Of note this 
study used the mouse clone 3H2 (Abgent, CA), which targets a region of 111 amino 
acids (aa 1216 to 1326) but is no longer commercially available. Patients with 
recurrent or metastatic disease who will be entering the growing number of clinical 
trials where a robust assessment of ARID1A protein expression in the tumour could 
be informative will require a test that is accurate, reproducible with a fast turn-around 
time.  
 
Here our aims were to develop ARID1A IHC as a surrogate predictive biomarker for 
diagnostic assessment of ARID1A mutational status in gynaecological tumours. In 
particular, we sought to compare the concordance of a number of commercially 
available antibodies using a standardised scoring system and identify the most 
optimal assay for clinical assessment of mutation status. 
 
MATERIALS AND METHODS 
Cell lines 
Cell lines ES2 and TOV21G were obtained from the American Type Tissue 
Collection (ATCC). HCT116 isogenic ARID1A (Q456*/Q456*) and parental lines were 
purchased from Horizon Discovery (Cambridge, UK). These are developed by knock-
in of premature stop codon (Q456*). Cell lines were cultured in a humidified 37°C 
incubator with 5% CO2. Cell lines were tested to confirm no mycoplasma infection 
using Mycoalert™ ®Mycoplasma Detection Kit as per manufacturer’s instructions 
(Lonza, Slough UK). Cell line identity was confirmed with short tandem repeat typing 
using the Promega GenePrint®10 system (Promega, Southampton, UK). Cell pellets 
were formalin fixed and paraffin-wax embedded (FFPE) for antibody optimisation.  
 
Clinical Samples 
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All patients gave written consent for the use of material for research purposes and 
tissue samples were obtained with appropriate ethical approval under the Royal 
Marsden Hospital (RMH) NHS Foundation Trust study: CCR3705 “Analysis of tumour 
specimens for biomarkers in gynaecological cancers” (Table 1, Supplementary Table 
S1). All patient samples were reviewed at RMH and appropriate FFPE tissue blocks 
were selected from their histology reports. Haematoxylin and Eosin (H&E) sections 
were reviewed by a pathologist (DK) to confirm appropriate tumour tissue and 
content. Five thick (eight μm) sections were cut for DNA extraction, with an additional 
H&E slide and three unstained sections for ARID1A immunohistochemistry (IHC). 
Whole serial sections were cut from the same diagnostic block to minimise 
heterogeneity between analysis for the ARID1A IHC and next-generation 
sequencing. If no germline blood sample was available, then non-malignant FFPE 
blocks were obtained and sections cut for DNA extraction. 
 
DNA extraction and library preparation 
DNA extraction and NGS sequencing took place in GCLP accredited laboratories at 
The Centre for Molecular Pathology, The Royal Marsden NHS Foundation Trust, 
Sutton. Genomic DNA from FFPE tissue sections was extracted using QIAamp FFPE 
Tissue Kit (Qiagen, Manchester, UK) according to the manufacturer’s instructions for 
both tumour and non-malignant content. Genomic DNA from blood was extracted 
using the QIAamp Blood mini kit (manual) or QIAsymphony DNA Midi Kit 
(automated) (Qiagen, Manchester, UK) according to the manufacturer’s instructions. 
DNA quality was assessed on the Agilent 2200 Tapestation (Agilent, Stockport, UK) 
and the Qubit Fluorometer (Fisher Scientific, Loughborough, UK).  
 
Targeted ARID1A sequencing 
ARID1A mutations were identified using a targeted capture panel (Nimblegen, 
Roche, Welwyn Garden City, UK), designed to target 59 genes for the FOrMAT 
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clinical trial (Feasibility of Molecular Characterisation Approach to Treatment, 
CCR3994, Royal Marsden NHS Hospital, Foundation Trust). The panel typically 
covers ARID1A at 99% >250X (Supplementary Table S2). Individual sample library 
preparation was performed using the KAPA Biosystem HyperPlus kit using 50-200ng 
DNA. Pooling and capture steps were performed using the Nimblegen SeqCap 
Capture Protocol (Roche). KAPA Library Quant Kit Universal qPCR Mix (Illumina), 
was used to quantify the libraries before combining in equimolar concentrations prior 
to sequencing on the Illumina MiSeq. A high confidence call covered >95% of a 
region; medium confidence >85% and a failure if the coverage was <85% coverage. 
MiSeq Reporter software (v2.5.1) was used to align sequences to version Hg19 of 
the human genome using aligner: BWA v0.61 and Somatic Caller v3.5.2.1 to call 
variants alongside in-house web server 1.0 and 2.0 software. Variants were called at 
a frequency of 5% and present in at least 5 reads, with a minimum read depth of 10 
reads. Mutations were manually visualised in the Integrated Genomics Viewer (IGV).  
All mutations were validated using a custom AmpliSeq panel (Thermo Fisher, 
Wilmington, USA) and run on the Ion Proton panel (Thermo Fisher, Wilmington, 
USA)  with 10 ng input DNA. Sequencing data was analysed using the Ion Torrent 
software suite (version 5.2.2). Sequences were aligned to version Hg19 of the 
human genome and mutations were called using the variantCaller (version 
v5.2.0.34). For pairs of tumour-normal samples, mutation calls were intersected 
using vcf-isec (VCFtools version 0.1.10) and filtered to retain somatic mutations. 
Oncotator and SnpEff (version 3.3h) were used to annotate somatic variants 
reporting the most deleterious effect. Further annotations were added to each 
mutation using ANNOVAR and the following databases: ClinVar, COSMIC, 
dbnsfp33a, clinvar_20170130, ljb23_ma, exac03 and exac03nontcga. Only those 
mutations that were confirmed with both sequencing platforms were included in the 
final concordance analysis. Raw targeted sequencing data have been deposited into 
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the NCBI Sequence Read Archive under the accession PRJNA432413 and 
PRJNA432343. 
 
ARID1A Immunohistochemistry  
IHC was performed on 3-4μm thick whole tissue sections. The slides were incubated 
with antibodies to: Anti-ARID1A, rabbit monoclonal 1:1000, EPR13501 (Abcam, 
Cambridge, UK), ARID1A/BAF250A, rabbit monoclonal 1:250, D2A8U (Cell Signaling 
Technology, Europe, Leiden, The Netherlands) and anti-ARID1A, rabbit polyclonal 
1:400, HPA005456 (Sigma-Aldrich, Gillingham, Dorset, UK), using the Dako-
Autostainer Link 48 with the EnVision FLEX kit as per manufacturer’s instructions 
(Agilent Technologies, Cheadle, Cheshire, UK). Human breast, prostate and kidney 
tissue were used as positive controls and xenograft models were obtained as 
previously described[24]. 
 
Cases were independently scored using an immunoreactive scoring system[30] by 
three pathologists DK (Pathologist 1) KN (Pathologist 2) and AA (Pathologist 3) who 
were blinded to the sequencing results. Sections were evaluated for both intensity 
(0=negative, 1= weak staining; 2= moderate; 3= strong) and proportion of cells 
staining positively expressed as a percentage (0= 0%; 1+ ≤10%; 2+= 11-50%; 3+= 
51-80%; 4+>80%). The intensity and proportion of cells staining was multiplied to get 
the final score between 0-12[30].  Stromal cells were used as an internal positive 
control. The pathologists’ scores were averaged to give a combined score used in 
further analyses. An IHC score “cut-off” for loss of expression was defined in 
conjunction with the genomic deleterious mutation results for each antibody using 
ROC statistical analysis. Fleiss kappa statistics were used to assess inter-rater 
variability[31]. 
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RESULTS 
ARID1A IHC optimisation shows nuclear immunoreactivity in ARID1A wild-type 
cases and absence in ARID1A mutant cases  
 
We first evaluated three ARID1A antibodies based upon their current availability and 
recent use in the literature[24, 32, 33]; Abcam EPR13501 monoclonal antibody, Cell 
Signaling D2A8U monoclonal antibody and Sigma HPA005456 polyclonal antibody, 
hereafter abbreviated to clone details (Figure 1A). Antibodies were optimised on 
human tissue, HCT116 ARID1A isogenic (mutant and wild-type) cell lines, ES2 
(ARID1A wild-type), TOV21G (ARID1A mutant) ovarian clear cell carcinoma cell lines 
and in HCT116 ARID1A isogenic xenograft models (Figure 1B-D). These cell lines 
are known to either express or not express ARID1A as previously evaluated by 
western blot (Supplementary Figure S1 and [24]).  Antibodies were diluted 
accordingly to ensure a contrast between mutant and wild-type cell lines. ARID1A 
immunoreactivity was detected in the nucleus, in both malignant epithelial tumour 
and stromal cells, which were used as a positive internal control in all samples.  Of all 
three antibodies tested, D2A8U showed the strongest immunoreactivity in the cell 
line models (Figure 1C), with background staining most visible with HPA005456.  
 
We next evaluated ARID1A protein expression in a cohort of 45 gynaecological 
cancers with all three antibodies (Figure 2 and Table 1). All 3 antibodies 
demonstrated ARID1A immunoreactivity and performed well on archival tissue, with 
the oldest block evaluated was from 2005 (3705-0481) and the most recent was from 
2016 (666179) (Table 2 and Supplementary Table S3). One case (3705-0541) was 
not fixed appropraiately at the time of resection and we were unable to process it for 
IHC, although we were able to extract good quality DNA. Twenty-four cases scored a 
maximum immunoreactive score of 12 with EPR13501, compared to 16 with D2A8U 
and 13 with HPA005456. Four cases scored 0 with EPR13501, 3 cases scored 0 
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with D2A8U and none scored 0 with HPA005456 (Table 2). The scoring concordance 
of the antibodies between the pathologists varied, with EPR13501 showing the best 
inter-rater agreement of 0.78, followed by D2A8U (0.67) and HPA005456 (0.57, 
Fleiss’ kappa statistics[31]) (Supplementary Table S4). 
 
Endometriosis related carcinomas show enrichment of ARID1A mutations  
 
ARID1A mutations were next evaluated using a 59-gene targeted DNA capture 
panel, followed by next generation sequencing with a median depth of 718X for 
ARID1A, (IQR=370X-1060X) (Figure 2, Supplementary Table S2). We were able to 
extract and sequence good quality DNA from archival FFPE blocks in 44 out of 45 
cases (exception: 3705-0051).  Twenty-five ARID1A mutations were identified in 16 
cases, of which 21 mutations were validated in 14 cases, and were spread 
throughout the gene, consistent with previous studies[1, 2] (Figure 3A, 
Supplementary Table S5). The frequency of mutations according to histological 
subtype were 39% (7/18) in OCCC, 57% (4/7) in endometrioid adenocarcinoma of 
the ovary, 17% (1/6, a pelvic carcinosarcoma case) in carcinosarcomas and 40% in 
endometrial carcinoma, (2/5, both endometrioid endometrial carcinomas) (Table 2 
and Figure 3B), in keeping with reported frequencies in the literature[2, 6, 34]. We 
identified 9 frameshift mutations, 11 nonsense mutations and 1 mis-sense mutation 
(Table 2 and Figure 3A and 3C-D). Six cases had more than 1 mutation (Table 2 and 
Figure 3C). The variant allele frequency (VAF) ranged from 0.07 to 0.59, with a 
number of the mutations showing a low VAF, suggesting subclonal tumour 
populations (e.g. case 3705-0464 with 2 mutations, with VAFs of  0.07 and 0.14). Of 
note, even with a low VAF, protein loss occurred (e.g. case a carcinosarcoma case, 
3705-0481 with a frame shift mutation (p.Pro1135fs) with a VAF of 0.19, scores of 0 
(EPR13501), 0 (D28AU) and  2 (HPA005456)), (Figure 3C). Two cases (3705-0553, 
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666179) had mutations that were not validated on the Ion Torrent (Supplementary 
Table S5) due to coverage issues.  
 
ARID1A immunoreactivity and mutational status show between 96-100% 
concordance in gynaecological cancers 
 
In order to assess if IHC could be used as a biomarker of mutation status, we next 
evaluated the concordance of ARID1A IHC with the validated mutations. Using 
Receiver Operating Characteristics (ROC) curve analysis we were able to define a 
cut-off for each antibody to reliably identify mutant cases. (Table 3). Concordance 
between mutated gynaecological carcinoma cases and the averaged IHC scores 
(Supplementary Table S3) were calculated, including a specific analysis for OCCC 
cases (Table 3). One out of the six carcinosarcomas, 3705-0500, was an outlier, as 
although it had two nonsense mutations (pTyr1377Ter, p.Glu1542Ter) at relatively 
high VAF’s (0.4), there was only a slight reduction in protein expression, scoring 5 
(EPR13501), 5 (D28AU) and 4 (HPA005456). Both subtypes of serous ovarian 
cancer, a mesonephric adenocarcinoma case and the small cell carcinomas of the 
ovary were ARID1A wild-type and showed high protein expression (with scores 
ranging between 11-12 (EPR13501), 11-12 (D28AU) and 6-12 (HPA005456) (Figure 
4). Of all three antibodies tested HPA005456 showed the widest range of scores 
(Figure 4B).  Seven OCCC cases were found to have ARID1A mutations; all of which 
showed a reduction in immunoreactivity (Figure 5). All OCCC ARID1A wild-type 
cases had detectable protein expression, with scores between 11-12 with 
EPR13501. 
 
DISCUSSION 
In this study, we assessed the concordance of three commercially available 
antibodies for the assessment of ARID1A protein expression as a surrogate 
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biomarker of mutation status. Overall, we found that IHC is an excellent surrogate 
biomarker of loss of function mutational status and were able to establish thresholds 
with each antibody to reliably identify mutant cases to be used in prospective patient 
assessment that improves upon published concordance rates.  
 
Concordance rates for all cases were 100% (EPR13501), 100% D2A8U and 97% 
(HPA005456). The histograms for all antibodies show that overall there is a clear bi-
modal distribution in immunoreactive scores between the mutant and wild-type 
cases, that is best exemplified with EPR13501 and D2A8U, with HPA005456 
showing the greatest variation, perhaps due to the polyclonal nature of the antibody, 
whereas the D2A8U and EPR13501 are monoclonal. For instance, comparing OCCC 
cases alone, our concordance was 100% with all antibodies, compared to 73% 
(27/37 samples) as reported by Wiegand et al[1]. Given that the number of OCCC 
mutant cases we assessed is small due to the rarity of cases and fact that trials 
combine gynaecological histologies, we propose utilising the cut-offs derived from all 
gynaecological cases. As all three antibodies had excellent specificity and sensitivity, 
other factors come into consideration when deciding which antibody to recommend 
taking forward for potential clinical use. The inter-pathologists scores were most 
consistent with EPR13501, and the dilution factor of 1:1000 for EPR13501 compared 
to D2A8U’s 1:250, which means that this would be more cost-effective with less 
batch-to-batch variation. D2A8U’s staining was most intense in cell line models, but 
weaker in human tissue, whereas EPR13501 had the strongest intensity in human 
tissue out of all three antibodies. We investigated HPA005456 as it had been used in 
a number of recent papers[33, 35, 36], however, as it is a rabbit polyclonal antibody, 
it will not be available for investigators once the stock runs out and is therefore not a 
long term viable option.  
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One of the limitations of this study is that even though we identified 45 patient 
samples initially, we were only able to assess 43 cases. However, the rarity of these 
tumours in general renders larger series challenging. In order to correct for this, we 
were stringent with our analysis of the sequencing data, including only cases where 
mutations were identified by both sequencing platforms. Thus, we could be confident 
with the mutation calls that we made. Overall, we have shown that IHC is generally 
concordant with mutational status; we did observe some variation in the 
carcinosarcoma cases, which may, in itself, reflect the heterogeneity of these 
tumours and the limitations of using an immunoreactive score. For example, in case 
3705-0500, this may be explained by the ARID1A mutation occurring after the 
ARID1A epitope sites and hence the detection of the truncated residual protein.  We 
observed one endometrioid ovarian adenocarcinoma with a small area of subclonal 
loss (Supplementary Figure S2). The patient did not have an identifiable ARID1A 
mutation and scored a 12 (>80% of tumour staining strongly). How such patients 
respond to targeted therapy will only be able to be evaluated in the context of a 
clinical trial. Of note, we did not identify any somatic in-frame deletions. However, 
given reports that such mutations affect the subcellular distribution of ARID1A[37], it 
would be interesting to assess this with the optimal antibody. 
 
Although a number of smaller studies have assessed concordance between ARID1A 
IHC and mutational status in gynaecological carcinomas, the concordance rates are 
lower than we report here and the antibody details and scoring systems used are not 
fully reported [29][31-33].  For instance, L’heureux et al analysed archival tissue by 
IHC and mutational status as part of a 40-patient phase II clinical trial in OCCC with 
ENMD-2076, an oral multi-targeted kinase inhibitor[38].  They had paired data for 32 
samples, with 19 ARID1A mutant cases and 13 wild-type cases, where the 
concordance of the mutational status with IHC was only 69%.  Furthermore, the 
antibody and specific scoring details and nature of mutations were however not 
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detailed. Guan et al compared ARID1A IHC and mutational status in uterine 
carcinomas using the Sigma polyclonal HPA005456 antibody (targeting 1266-1370 
amino acids), with negativity defined as absence of nuclear staining, and identified 
that only 50% (5/10) of cases with deleterious mutations showed complete lack of 
ARID1A expression. Our study only included gynaecological tumours and would 
need to be extended to other tumour types to ascertain its general applicability.  
 
A recent sequencing study identified cancer-associated inactivating ARID1A 
mutations in deep infiltrating endometriosis, with loss of ARID1A immunoreactivity 
serving as a surrogate for ARID1A inactivating mutations using the HPA005456 
antibody[36]. Using the monoclonal EPR13501 antibody, which had the best inter-
rater agreement in our study, would allow comprehensive analysis of endometriosis 
to determine the clinical significance of ARID1A loss and be of potential diagnostic 
use.  
 
In conclusion, we have systematically assessed a number of commercially available 
antibodies and identified EPR13501 as a robust biomarker of ARID1A status with a 
cut-off of <8 using our optimised scoring system. This will be useful for recruiting 
patients for clinical trials based on ARID1A mutational status. An international 
academic trial of ATR inhibition in combination with a PARP inhibitor in ARID1A-
stratified gynaecological cancers that utilises our findings is planned to open in 2018 
using this approach, allowing validation and evaluation of the IHC scoring system in 
the context of a prospective clinical trial.  
 
ACKNOWLEDGEMENTS 
We thank Breast Cancer Now Histopathology Unit, The Centre for Molecular 
Pathology and the Gynaecology Research Team at The Royal Marsden NHS 
Foundation Trust, The Breast Cancer Now Bioinformatics Core and members of the 
 18 
The Functional Genomics Labroratory at the Institute for Cancer Research. This work 
was funded by the Gynaecological Cancer Fund, The Royal Marsden Charity, Breast 
Cancer Now , as part of programmatic funding for RN and CJL, Cancer Research UK 
as part of programme grant funding to CJL and The Monument Trust. We 
acknowledge NHS funding to the NIHR Royal Marsden Hospital Biomedical 
Research Centre. 
 
AUTHOR CONTRIBUTIONS 
RN, CJL and SB conceived and designed the study. SK, KN, AA, DK, FD, AL,  TJ, 
MH, KF and NM carried out the experiments and undertook IHC scoring. JC, TJ, MH, 
AGR and RN performed the bioinformatics analysis. SK, KN, AA, DK, FD, CJL, SB 
discussed and interpreted the results. SK, CJL, SB and RN wrote the first draft. All 
authors read and approved the final manuscript.  
 
LIST OF ONLINE SUPPORTING MATERIAL 
Supplementary Figure S1: ARID1A status of OCCC cell lines. Western blot of 
ARID1A protein expression in ES2 (OCCC ARID1A wild-type cell line) and TOV21G 
(OCCC ARID1A mutant cell line). ARID1A (250 kDa fragment), loading control -
Actin (42 kDa). 
 
Supplementary Figure S2: Subclonal expression in a Grade 2 endometrioid 
adenocarcinoma of the ovary case (3705-0482). Images of area of subclonal 
expression with IHC scores and sequencing results. Top Row: Low power 
magnification, arrow shows area of negative protein expression surrounded by area 
of positive expression with all 3 antibodies (scale bar 1mm). Bottom Row: High 
power magnification, arrow shows area of negative protein expression surrounded by 
area of positive expression with all 3 antibodies (scale bar 100µm). 
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Supplementary Table S1: Extended table of clinicopathlogical features of patient 
cohort 
Supplementary Table S2: Summary of ARID1A sequencing metrics from targeted 
capture panel  
Supplementary table S3: Summary of individual and combined scores for ARID1A 
IHC  
Supplementary Table S4: Inter-pathologist concordance metrics 
Supplementary Table S5: Summary of ARID1A mutations identified and validation 
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Figure legends 
Figure 1. ARID1A antibody optimisation in tumour cell lines and tumour 
xenograft models 
(A) Schematic of ARID1A protein illustrating epitope regions raised against all 3 
antibodies studied. The lollipop plot shows mutation loci of two cell lines used in 
antibody optimisation: HCT116 ARID1A isogenic mutant cell line Q456*/Q456*, 
nonsense mutation (depicted in orange) and TOV21G, a compound heterogeneous 
cell line with mutation loci: TOV21G p.548fs and p.756fs, frameshift mutations 
(depicted in mauve).  (B)  Immunoreactivity of ARID1A detected by all three 
antibodies in HCT116 ARID1A isogenic cell lines embedded in FFPE blocks. 
HCT116 -/- (ARID1A mutant) shows loss of ARID1A immunoreactivity whereas 
nuclear immunoreactivity was preserved in the HCT116 +/+ (ARID1A wild-type) cell 
line. EPR13501, rabbit monoclonal, antigen retrieval using microwave and dilution 
1:1000.  D2A8U, rabbit monoclonal, antigen retrieval with pre-treatment module and 
dilution 1:250. HPA005456, rabbit polyclonal, antigen retrieval with pre-treatment 
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module and dilution 1:400. Scale bar is equal to 100µm. (C) ARID1A 
immunoreactivity in ovarian clear cell carcinoma cell lines and HCT116 +/+ and -/- 
cells engrafted as xenografts was detected with all three antibodies in ovarian clear 
cell carcinoma cell lines. TOV21G (ARID1A mutant) shows loss of ARID1A 
immunoreactivity whereas immunoreactivity was preserved in the ES2 (ARID1A wild-
type) cell line. Scale bar is equal to 100µm. D. ARID1A immunoreactivity was 
detected with all three antibodies in xenograft models of HCT116 +/+ and HCT116 -/-
. The background staining seen in cell lines was reduced in xenografts. Scale bar is 
equal to 100µm. 
 
Figure 2. Study workflow  
Modified CONSORT diagram showing the processing of the 45 gynaecological 
cancer cases identified. After histopathology review a representative block was 
chosen. The same FFPE block was used for extracting DNA for next-generation 
sequencing (NGS) and immunohistochemistry (IHC). One case failed NGS quality 
control and one case was not suitable for IHC analysis. Three histopathologists 
independently reviewed and scored cases. These were then averaged and 
compared to mutational status to establish concordance (n=43).  
 
Figure 3. Distribution of ARID1A mutations identified by targeted sequencing 
in gynaecological cancers. 
 
(A) A lollipop plot showing the distribution and classes of validated loss of function 
mutations in ARID1A detected by both sequencing platforms in 44 cases. Twenty-
one ARID1A mutations were identified in 14 patients. The majority were frameshift 
mutations (9, in mauve), with 11 nonsense mutations (orange) and 1 missense 
mutation (green). (B) Bar chart showing the frequency of ARID1A mutations 
according to histology. An enrichment of ARID1A mutations was seen in 
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endometriosis-related tumours and carcinosarcomas; with 57% of ovarian 
endometroid (light blue (and 39% of OCCC (dark blue) cases having an ARID1A 
mutation.  (C) A variant allele frequency plot shows each case with the type of 
validated mutation (colour of circle) and coverage (size of circle) with corresponding 
protein expression on IHC (boxes below). Six cases had more than 1 mutation in 
ARID1A. Case 3705-0541 was not suitable for IHC processing.  
 
Figure 4. ARIDIA immunohistochemistry shows good concordance with 
mutational analysis for all three antibodies in a variety of gynaecological 
cancers 
(A) ARID1A immunoreactivity in grade 2 endometrioid adenocarcinoma of the ovary. 
Case 3705-0460 with 1 mutation (p.Arg1505Ter), shows a lack of tumour cell 
staining with positive stromal staining (immunoreactive score with EPR13501: 1, 
D2A8U: 1 and HPA005456: 3). Case 3705-0529, ARID1A wild-type, shows positive 
nuclear staining with an immunoreactive score with EPR13501: 12, D2A8U: 12 and 
HPA005456: 9. Scale bar is equal to 100µm. (B) Histograms showing the distribution 
of all immunoreactive scores (n=37) with all 3 antibodies, annotated with mutational 
status. The majority of ARID1A mutant cases (red) show low immunoreactivity 
scores and ARID1A wild-type cases (blue) show high immunoreactivity scores. There 
is greatest variation in the HPA005456 scores.  
 
Figure 5. ARIDIA immunohistochemistry shows good concordance with 
mutational analysis for all three antibodies in OCCC 
 
ARID1A immunoreactivity in OCCC. Case 3705-0416 with 2 mutations (p.Gly191fs, 
p.Tyr485Ter), shows a lack of tumour cell staining with positive stromal staining 
(immunoreactive score with EPR13501: 0, D2A8U: 1 and HPA005456: 2). Case 
3705-0514, ARID1A wild-type, shows positive nuclear staining with an 
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immunoreactive score with EPR13501: 12, D2A8U: 11 and HPA005456: 12. Scale 
bar is equal to 100µm. (B) Histogram showing immunoreactivity scores for OCCC 
cases shows a bimodal distribution between mutant cases that lead to loss of 
immunoreactivity and ARID1A wild-type cases
 Tables 
Table 1: Overview of patient characteristics in the study. 
Patients were aged between 21 and 76 years of age, and comprised 8 
gynaecological subtypes, the most frequent being clear cell carcinoma of the ovary, 
n=18.  
 
Parameter Total 
number (n) 
Number of tumour samples 45 
Diagnosis  
Carcinosarcoma (CS) 6 
Endometrial Clear Cell (ECC) 1 
Endometrioid Adenocarcinoma of the Endometrium (EAE) 4 
Endometrioid Ovarian Carcinoma (ENOC) 7 
Low Grade Serous Ovarian Carcinoma (LGSOC) 3 
High Grade Serous Ovarian Carcinoma (HGSOC) 1 
Small Cell Carcinoma of the Ovary, Hypercalcaemic Type (SCCOHT) 2 
Mesonephric Adenocarcinoma of the Ovary (MAO) 1 
Mesonephric Adenocarcinoma of the Ovary and Endometrium (MAOE) 1 
Serous Ovarian Carcinoma/Carcinosarcoma (SOC/CS) 1 
Ovarian Clear Cell Carcinoma (OCCC) 18 
Grade  
I 6 
II 8 
III 31 
FIGO stage  
I 14 
II 14 
III 13 
IV 4 
Median age, y (range) 57, (21-76) 
Endometriosis  
Yes 16 
No 28 
N/A 1 
Primary Specimen  
Yes 42 
No 3 
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Table 2 
Summary of averaged pathologist IHC scores and validated sequencing results for 
ARID1A.  *Matched patient lung metastasis, ns= not specified, CS=carcinosarcoma 
of the ovary, ECC=Endometrial Clear Cell, EAE=Endometroid Adenocarcinoma of 
the Endometrium, ENOC=Endometrioid Ovarian Carcinoma, LGOSC=Low Grade 
Serous Ovarian Carcinoma, HGSOC= High Grade Serous Ovarian Carcinoma, 
SCCOHT=Small Cell Carcinoma of the Ovary, Hypercalcaemic Type, 
MAO=Mesonephric Adenocarcinoma of the Ovary, MAOE=Mesonephric 
Adenocarcinoma of the Ovary and Endometrium, UDC=Undifferentiated Component, 
SOC/CS=Serous Ovarian Carcinoma/Carcinosarcoma and OCCC=Ovarian Clear 
Cell Carcinoma. 
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Patient 
Identifier 
Diagnosis 
IHC ARID1A 
antibody 
EPR13501 
average 
score 
(Pathologists 
1,2, and 3) 
IHC ARID1A 
antibody 
D2A8U 
average 
score 
(Pathologists 
1,2, and 3) 
IHC ARID1A 
antibody 
HPA005456 
average 
score 
(Pathologists 
1,2, and 3) 
IHC: 
ARID1A 
protein 
loss 
Sequencing: 
ARID1A 
mutation and 
protein 
change 
3705-
0449 
CS 12 11 10 no no 
3705-
0456 
CS 10 11 9 no no 
3705-
0470 
CS 12 
8 
10 no no 
3705-
0484 
CS 12 12 12 no no 
3705-
0500 
CS 5 5 4 yes p.Tyr1377Ter, 
p.Glu1542Ter 
3705-
0510 
CS 12 
12 
8 no no 
666179 ECC 12 11 8 no no 
3705-
0553 
EAE 
(UDC) 
9 6 7 no no 
3705-
0341 
EAO 12 11 9 
no 
no 
3705-
0481 
EAO 0 0 
2 
yes p.Pro1135fs 
3705-
0541 
EAO NA NA NA NA p.Gln428Ter 
3705-
0323 
EAO 3 
3 
6 yes  p.Gln512Ter, 
p.Arg1899Ter 
3705-
0460 
EAO 1 1 3 yes p.Arg1505Ter 
3705-
0482 
EAO 12 12 12 no no 
3705-
0529 
EAO 12 12 9 no no 
3705-
0199 
EAE 3 2 1 yes p.Ile1975fs, 
p.Gln799fs 
3705- EAE 1 1 1 yes p.Arg1504Ter 
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0438 
3705-
0548 
EAE 12 11 12 no no 
3705-
0475 
HGSOC 12 12 12 no no 
3705-
0487 
LGSOC 
11 
12 11 no no 
3705-
0493 
LGSOC 12 12 12 no no 
3705-
0525 
LGSOC 11 11 6 no no 
3705-
0051 
MAO 12 11 12 no NA failed 
sequencing 
QC 
3705-
0308 
MAOE 12 
12 
7 no no 
3705-
0442 
SOC/CS 12 12 10 no no 
3705-
0142 
OCCC 7 1 4 yes  p.Pro7fs 
3705-
0145 
OCCC 0 
3 
2 yes p.Ser614Ter 
3705-
0207 
OCCC 12 10 8 no no 
3705-
0346 
OCCC 2 1 
3 
yes p.Ala42fs, 
p.GLn723Ter 
3705-
0379 
OCCC 12 11 12 no no 
3705-
0383 
OCCC 12 11 11 no no 
3705-
0416 
OCCC 0 1 2 yes p.Gly191fs, 
p.Tyr485Ter 
3705-
0435 
OCCC 11 12 8 no no 
3705-
0453 
OCCC 12 12 9 no no 
3705-
0464 
OCCC 1 1 1 yes p.Gly1848fs, 
p.Ile2275Ser, 
p.Gln2070Ter 
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3705-
0468 
OCCC 12 11 12 no no 
3705-
0497 
OCCC 
12 
12 12 no no 
3705-
0514 
OCCC 12 11 12 no no 
3705-
0540 
OCCC 1 0 1 yes p.Gln932fs 
3705-
0544 
OCCC 12 12 12 no no 
3705-
0545 
OCCC 0 0 3 yes p.Gly319fs, 
p.Leu1100fs 
3705-
0558 
OCCC 11 11 11 no no 
3705-
0435* 
OCCC  
12 
12 12 no no 
3705-
0466 
SCCOHT 12 12 12 no no 
3705-
0551 
SCCOHT 12 12 12 no no 
 
 
Table 3: ROC curve analysis to define mutant immunoreactive score and 
concordance 
 
 
Antibody All 
gynaecological 
cases: 
ARID1A mutant 
score 
Concordance 
(%) 
OCCC cases 
ARID1A 
mutant score 
Concordance 
(%) 
EPR13501 <8 100 <9 100 
100% sensitivity and 
100% specificity 
100% sensitivity 
and 100% 
specificity 
D2A8U <5.5 100 <6 100 
100% sensitivity and 
100% specificity 
100% sensitivity 
and 100% 
specificity 
HPA005456 <6.5 97 <6.5 100 
100% sensitivity and 
96% specificity 
100% sensitivity 
and 100% 
specificity 
 
